poisar

Stock

TG Therapeutics, Inc. TGTX

$55.71+1.33%

Overview

TGTX market data

Price History

TGTX price chart · 1M
O
54.73
H
55.97
L
54.37
C
55.71
Vol
68,589.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$54.73
Previous Close
$54.98
Day High
$55.97
Day Low
$54.37
52 Week High
$59.30
52 Week Low
$33.27
7 Day Return
+10.18%
30 Day Return
+1.54%
90 Day Return
+46.86%
1 Year Return
+65.85%
Daily Notional Volume
$3.8M
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
16.62
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$2.77
Diluted earnings per share over the trailing twelve months.
Beta
1.80
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
55.2%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$26.76 – $59.30
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $7.3B · P/B 21.07 · P/S 9.18.

Company News

10 captured
MARA Holdings, Coinbase Global, Ternium And Other Big Stocks Moving Higher On FridayBenzinga · Aug 21, 2026, 2:18 PM
Watching TG Therapeutics; Traders Speculate Multiple Parties Interested To Acquire TG TherapeuticsBenzinga · Aug 21, 2026, 1:47 PM
JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $72Benzinga · Aug 7, 2026, 4:51 PM
TG Therapeutics shares are trading lower after the company reported worse-than-expected Q2 EPS results.Benzinga · Aug 3, 2026, 2:12 PM
8-K filing — TG THERAPEUTICS, INC. (TGTX)SEC EDGAR · Aug 3, 2026, 11:05 AM
TG Therapeutics Raises FY2026 Sales Guidance from $925.000M to $950.000M vs $942.370M EstBenzinga · Aug 3, 2026, 11:00 AM
TG Therapeutics Q2 EPS $0.05 Misses $0.33 Estimate, Sales $240.335M Beat $229.721M EstimateBenzinga · Aug 3, 2026, 11:00 AM
B. Riley Securities Maintains Buy on TG Therapeutics, Raises Price Target to $86Benzinga · Jul 27, 2026, 5:39 PM
Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law FirmGlobenewswire Inc · Jul 17, 2026, 11:15 AM
HC Wainwright & Co. Maintains Buy on TG Therapeutics, Raises Price Target to $77Benzinga · Jul 13, 2026, 9:59 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock